Viral Genetics is a publicly traded biotechnology company that discovers and develops immune-based therapy technologies for HIV/AIDS. The company utilizes the Thymus Nuclear Protein technology. It also develops technologies for the treatment of infectious, autoimmune, and immunological deficiency disorders. The company s VGV-1 product is an investigational drug for clinical studies. It works in collaboration with the University of Colorado. Viral Genetics operates a subsidiary, V-Clip Pharmaceuticals.
Partial Data by Infogroup (c) 2024. All rights reserved.